

Paper No. ____
Filed: March 16, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS, INC.
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD.
Patent Owner

Case IPR2016-00626
U.S. Patent 8,784,789

PATENT OWNER'S MANDATORY NOTICES
PURSUANT TO 37 C.F.R. § 42.8

Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Senju Pharmaceutical Co., Ltd. hereby submits the following mandatory notices in connection with this proceeding.

I. SENJU'S POWER OF ATTORNEY

A Power of Attorney appointing lead and back-up counsel is being filed concurrently with these Notices.

II. SENJU'S MANDATORY NOTICES

(a) 37 C.F.R. § 42.8(b)(1): Real Party-in-Interest

The real party-in-interest for the Patent Owner is Senju Pharmaceutical Co., Ltd. Other real parties-in-interest include Bausch & Lomb Incorporated and Bausch & Lomb Pharma Holdings Corp.

(b) Related Matters

1. Judicial

The patent challenged here, U.S. Patent 8,784,789 (“the ’789 patent”), has been asserted in *Bausch & Lomb Incorporated, Bausch & Lomb Pharma Holdings Corp. and Senju Pharm. Co., Ltd. v. Micro Labs USA, Inc. and Micro Labs Limited*, Civil Action No. 1:14-cv-07406-NLH-JS, in the United States District Court for the District of New Jersey, filed on November 26, 2014. There is a related patent, U.S. Patent No. 8,877,168 (“the ’168 patent”), that is currently

involved in a parallel district court proceeding. As the Patent Owner reads 37 C.F.R. § 42.8, Patent Owner is not required to individually identify the proceeding, but if the Board prefers it identified, Patent Owner will do so.

2. Administrative

Patent Owner notes the existence of U.S. Patent No. 8,883,825 (“the ’825 patent”), which issued on November 11, 2014, based on U.S. Patent Application No. 13/599,212, which is a division of the ’789 patent. Patent Owner also notes the existence of pending U.S. Application No. 14/511,393, which is a continuation of the ’825 patent.

(b) 37 C.F.R. § 42.8(b)(3) and (4): Lead and Back-Up Counsel, and Service Information

Senju designates the following counsel to transact all business in the United States Patent & Trademark Office associated with the above-captioned proceeding.

Lead Counsel	Back-Up Counsel
Bryan C. Diner (Reg. No. 32,409) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-4116 Fax: (202) 408-4400 Email: Bryan.Diner@finnegan.com	Justin J. Hasford (Reg. No. 62,180) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-4175 Fax: (202) 408-4400 Email: Justin.Hasford@finnegan.com Joshua L. Goldberg (Reg. No. 59,369) Finnegan, Henderson, Farabow,

	Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-6092 Fax: (202) 408-4400 Email: Joshua.Goldberg@finnegan.com
--	--

Please address all correspondence regarding this proceeding to lead and back-up counsel. Senju consents to electronic service by email.

Respectfully submitted,

Dated: March 16, 2016

By: /Joshua L. Goldberg/
Joshua L. Goldberg, Back-Up Counsel
Reg. No. 59,369

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Mandatory Notices** was served on March 16, 2016, via email directed to counsel of record for the Petitioner at the following:

Jitendra Malik, Ph.D.
jitty.malik@alston.com

Hidetada James Abe
james.abe@alston.com

Lance Soderstrom
lance.soderstrom@alston.com

Joseph M. Janusz
Joe.janusz@alston.com

Date: March 16, 2016

/Bradley J. Moore/

Bradley J. Moore
Litigation Legal Assistant

Finnegan, Henderson, Farabow, Garrett &
Dunner, LLP